RxDoctor Payments Data

Dustin Nguyen, MD

Internal Medicine · New York, NYNPI 1831196898

Payments from drug & device makers

$4,255in general payments, 2019–2025

Across 46 payments — averaging $92.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$3K
  • Gilead$633
  • Amgen$167
  • GSK$154
  • AstraZeneca$130
  • Johnson & Johnson$120
  • plus $51 from 3 others

What the payments were for

  • Speaking & faculty fees$3,00071%
  • Food & beverage$1,24329%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,255 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$413,929
Medicare patients
258
Services billed
4,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl2,338$1,399,566
JardianceEmpagliflozin619$594,246
VemlidyTenofovir Alafenamide220$348,869
RybelsusSemaglutide192$293,502
LicartDiclofenac Epolamine310$283,061
FarxigaDapagliflozin Propanediol274$277,770
JanuviaSitagliptin Phosphate256$269,112
Repatha PushtronexEvolocumab270$196,708
Breo ElliptaFluticasone/Vilanterol235$178,442
TrulicityDulaglutide113$158,950
Dupixent SyringeDupilumab35$151,897
Trelegy ElliptaFluticasone/Umeclidin/Vilanter131$151,064
LinzessLinaclotide161$148,876
ProliaDenosumab75$123,357
MounjaroTirzepatide78$119,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Jentadueto$21$698,372757 claims
GileadVemlidy$633$348,869220 claims
GSKBreo Ellipta, Trelegy Ellipta$154$329,506366 claims
AstraZenecaFarxiga, Nexium$130$326,650373 claims
Lilly USA, LLCTrulicity, Mounjaro$12$278,941191 claims
AbbVieLinzess, Restasis, Creon$18$239,021232 claims
AmgenProlia$167$123,35775 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →